Hyperion Defi, Inc. · NASDAQ:HYPD
Hyperion Defi — Eyenovia — Investor Presentation (August 2023)
15 slides from Hyperion Defi's investor presentation, Aug 16, 2023
Slide 1: Boldly Go Where Eyecare Has Never Gone Before
Boldly Go Where Eyecare H a s Never Gone Before August 2023
Slide 2: Forward looking statements
Forward looking statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forwar d - looking statements. Forward - looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations
Slide 3: The Optejet boldly brings eyecare into the 21st Century
The Optejet ® boldly brings eyecare into the 21st Century 1. German, E., Hurst, M. & Wood, D. Reliability of drop size from multi - dose eye drop bottles: is it cause for concern?. Eye 13, 93 – 100 (1999). https://doi.org/10.1038/eye.1999.17. | Ahmed, S., Amin, M.M. & Sayed, S. Ocular Drug Delivery:
Slide 4: Is the Optejet the best option to address the limitations of topical ophthalmic drug delivery?
● Usability 1 ● No head - tilting ● Fixation light assist ● Push of a button ● Tolerability 2 ● Lower drug and preservative exposure ● Less ocular impact ● Less systemic exposure ● Connectivity 3 ● To mobile device for dose reminders and compliance support ● To the cloud for healthcare system patien
Slide 5: Where the Optejet can make a bold difference
Where the Optejet ® can make a bold difference Market Opportunity 1 Usability Tolerability Connectivity Pediatric Myopia $4.5B Dry Eye $3.6B Glaucoma $3.0B Presbyopia $0.9B Mydriasis $0.3B Total $12.3B 1. Estimates from various sources
Slide 6: MydCombi: Mydriasis as it has never been done before
MydCombi ʏ : Mydriasis as it has never been done before + Only fixed combination of the most used dilating medications in the US + Only ophthalmic spray approved for mydriasis = Together, designed to streamline the pupil dilation process ● Efficacy 1 ● 61% of patients fully dilated in 20min; nearly
Slide 7: Clobetasol: A potent steroid with a future in the Optejet
Clobetasol 1 : A potent steroid with a future in the Optejet ® ● Eyenovia licensed the US rights to this unique post - surgical eye drop ● PDUFA date of March 2024 ● Provides significant short and mid - term revenue opportunity ($1.3B market size) ● Synergistic commercialization with MydCombi ʏ ● Po
Slide 8: Optejet technology will be targeted for Dry Eye
O p tejet ® technology will be targeted for Dry Eye ● Clobetasol may provide a unique profile that has the promise of quick relief and the ability to use alongside other drugs ● Optejet would provide a lower dose and added safety margin ● When developed with clobetasol, or another molecule, the Opte
Slide 9: Apersure: Your invisible second pair of glasses
Apersure ʏ : Your invisible second pair of glasses ● Target population is 40 - 55 year olds who have never needed vision correction prior to the onset of presbyopia in the top half of income ● Apersure provides functional vision for approximately 4 hours post - dose with very few side effects ● Opto
Slide 10: Optejet technology will be targeted for Glaucoma
● A full line of products, all in the Optejet ● PGAs, Beta Blockers, CAIs, Rock Inhibitors, etc. ● All may benefit from Optejet delivery ● Addressing significant issues in the treatment of glaucoma 1 ● Compliance ● Tolerability and side effects ● Ease of use ● Equipping HCPs with compliance data all
Slide 11: Changing how glaucoma is managed with the Optejet
Changing how glaucoma is managed with the Optejet ® ● The Optejet records each dose administered and can send information to a companion app ● Companion app could: ● Track compliance rates ● Send patient dosing reminders ● Share information with HCPs via the cloud ● Be used by healthcare systems and
Slide 12: By 2030, Optejet technology is expected to underpin major launches in the US and China
By 2030, O p tejet ® technology is expected to underpin major launches in the US and China ● Pediatric Myopia affects 41% of US children and 52% of Chinese children ● The highest - risk children are put on atropine drops to slow the progression ● Children take these drops for years ● Compliance issu
Slide 13: A string of catalysts anticipated over the next six years
A string of catalysts anticipated over the next six years 2024 2025 2026 2027 2028 2029 Partners launch myopia products MydCombi FDA Approval May 2023 Apersure FDA Approval Optejet enters market for glaucoma (multiple products) Optejet enters market for dry eye Clobetasol FDA Approval 2023 $250M Mar
Slide 14: Eyenovia. Boldly moving eyecare into the future.
Eyenovia. Boldly moving eyecare into the future. ● The first FDA - approved metered spray ophthalmic product ● Now commercializing MydCombi ● Second product (clobetasol) with PDUFA date in March, 2024 and potential for a dry eye indication ● Apersure (presbyopia) potential approval 4Q 2025 ● Inbound
Slide 15: Thank you
Thank you NASDAQ: EYEN